XML 34 R22.htm IDEA: XBRL DOCUMENT
v3.25.2

Collaborative Research and Development Agreements (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2025
Revenue from Contract with Customer [Abstract] |
Schedule of Milestones Achieved | Milestones under the GSK Agreement are as follows:
| PD-1 (Jemperli/Dostarlimab) |  | TIM-3 (GSK4069889/Cobolimab) |  |
Milestone Event | Amount | Quarter Recognized |  | Amount | Quarter Recognized |  |  |
Initiated in vivo toxicology studies using good laboratory practices (GLPs) | $1.0M | Q2'15 |  | $1.0M | Q4'15 |  |  |
IND clearance from the FDA | $4.0M | Q1'16 |  | $4.0M | Q2'16 |  |  |
Phase 2 clinical trial initiation | $3.0M | Q2'17 |  | $3.0M | Q4'17 |  |  |
Phase 3 clinical trial initiation - first indication | $5.0M | Q3'18 |  | $5.0M | Q4'22 |  |  |
Phase 3 clinical trial initiation - second indication | $5.0M | Q2'19 |  | $5.0M | — |  |  |
Filing of the first BLA(1) - first indication | $10.0M | Q1'20 |  | $10.0M | — |  |  |
Filing of the first MAA(2) - first indication | $5.0M | Q1'20 |  | $5.0M | — |  |  |
Filing of the first BLA - second indication | $10.0M | Q1'21 |  | $10.0M | — |  |  |
First BLA approval - first indication | $20.0M | Q2'21 |  | $20.0M | — |  |  |
First MAA approval - first indication | $10.0M | Q2'21 |  | $10.0M | — |  |  |
First BLA approval - second indication | $20.0M | Q3'21 |  | $20.0M | — |  |  |
Filing of the first MAA - second indication(3) | $5.0M | — |  | $5.0M | — |  |  |
First MAA approval - second indication(3) | $10.0M | — |  | $10.0M | — |  |  |
First commercial sales milestone(3) | $15.0M | Q3'24 |  | $15.0M | — |  |  |
Second commercial sales milestone(3) | $25.0M | Q4'24 |  | $25.0M | — |  |  |
Third commercial sales milestone(3) | $50.0M | — |  | $50.0M | — |  |  |
Fourth commercial sales milestone (4) | $75.0M | — |  | $75.0M | — |  |  |
Milestones recognized through June 30, 2025 | $133.0M | — |  | $13.0M | — |  |  |
Milestones that may be recognized in the future | $140.0M | — |  | $260.0M | — |  |  |
(1)Biologics License Application (“BLA”) (2)Marketing Authorization Application (“MAA”) (3)For Jemperli, the filing and approval of the first MAA for a second indication and first three commercial sales milestones are included as part of the royalty monetization agreement with Sagard (as defined below), see Note 5. Cash is generally received within 30 days of milestone achievement. (4)For Jemperli, we retained the rights to a $75.0 million sales milestone when Jemperli annual net sales exceed $1.0 billion. We are also eligible to receive a 10% royalty on net sales, as well as the following milestones under the Vanda License Agreement:
Milestone Event | Amount | Quarter Recognized
FDA regulatory approval for marketing of first licensed product in the USA for the treatment of active flares in GPP | $5.0M | —
Regulatory approval for marketing of the first licensed product in the EU | $5.0M | —
Commercial sales first exceed $100.0 million | $25.0M | —
Milestones recognized through June 30, 2025 | — | —
Milestones that may be recognized in the future | $35.0M | —

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration